Literature DB >> 23332226

Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer.

Piernicola Pedicini1, Lidia Strigari, Marcello Benassi.   

Abstract

PURPOSE: To determine a self-consistent set of radiobiological parameters in prostate cancer. METHODS AND MATERIALS: A method to estimate intrinsic radiosensitivity (α), fractionation sensitivity (α/β), repopulation doubling time, number of clonogens, and kick-off time for accelerated repopulation of prostate cancer has been developed. Based on the generalized linear-quadratic model and without assuming the isoeffective hypothesis, the potential applications of the method were investigated using the clinical outcome of biochemical relapse-free survival recently reviewed in the literature. The strengths and limitations of the method, regarding the fitted parameters and 95% confidence intervals (CIs), are also discussed.
RESULTS: Our best estimate of α/β is 2.96 Gy (95% CI 2.41-3.53 Gy). The corresponding α value is 0.16 Gy(-1) (95% CI 0.14-0.18 Gy(-1)), which is compatible with a realistic number of clonogens: 6.5 × 10(6) (95% CI 1.5 × 10(6)-2.1 × 10(7)). The estimated cell doubling time is 5.1 days (95% CI 4.2-7.2 days), very low if compared with that reported in the literature. This corresponds to the dose required to offset the repopulation occurring in 1 day of 0.52 Gy/d (95% CI 0.32-0.68 Gy/d). However, a long kick-off time of 31 days (95% CI 22-41 days) from the start of radiation therapy was found.
CONCLUSION: The proposed analytic/graphic method has allowed the fitting of clinical data, providing a self-consistent set of radiobiological parameters for prostate cancer. With our analysis we confirm a low value for α/β with a correspondingly high value of intrinsic radiosensitivity, a realistic average number of clonogens, a long kick-off time for accelerated repopulation, and a surprisingly fast repopulation that suggests the involvement of subpopulations of specifically tumorigenic stem cells during continuing radiation therapy.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23332226     DOI: 10.1016/j.ijrobp.2012.11.033

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  SBRT and extreme hypofractionation: A new era in prostate cancer treatments?

Authors:  Filippo Alongi; Alba Fiorentino; Berardino De Bari
Journal:  Rep Pract Oncol Radiother       Date:  2014-10-22

Review 2.  The evolution of practical radiobiological modelling.

Authors:  B Jones; R G Dale
Journal:  Br J Radiol       Date:  2018-03-20       Impact factor: 3.039

3.  Heuristic estimation of the α/β ratio for a cohort of Mexican patients with prostate cancer treated with external radiotherapy techniques.

Authors:  Christian S Adame González; José Trinidad Álvarez Romero; Mario Moranchel Y Rodríguez; Armando Félix Leyva; Michelle Aline Villavicencio Queijeiro; María Yicel Bautista Hernández
Journal:  Rep Pract Oncol Radiother       Date:  2021-09-30

4.  Clinical radiobiology of head and neck cancer: the hypothesis of stem cell activation.

Authors:  P Pedicini; R Caivano; A Fiorentino; L Strigari
Journal:  Clin Transl Oncol       Date:  2014-12-09       Impact factor: 3.405

5.  Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma.

Authors:  P Pedicini; A Fiorentino; G Improta; A Nappi; M Salvatore; G Storto
Journal:  Clin Transl Oncol       Date:  2013-03-05       Impact factor: 3.405

6.  Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes.

Authors:  Piernicola Pedicini; Alba Fiorentino; Vittorio Simeon; Paolo Tini; Costanza Chiumento; Luigi Pirtoli; Marco Salvatore; Giovanni Storto
Journal:  Strahlenther Onkol       Date:  2014-04-04       Impact factor: 3.621

Review 7.  Prostate cancer dose-response, fractionation sensitivity and repopulation parameters evaluation from 25 international radiotherapy outcome data sets.

Authors:  Matteo Tamponi; Domenico Gabriele; Angelo Maggio; Michele Stasi; Giovanni B Meloni; Maurizio Conti; Pietro Gabriele
Journal:  Br J Radiol       Date:  2019-04-24       Impact factor: 3.039

8.  Multivariate normal tissue complication probability modeling of gastrointestinal toxicity after external beam radiotherapy for localized prostate cancer.

Authors:  Laura Cella; Vittoria D'Avino; Raffaele Liuzzi; Manuel Conson; Francesca Doria; Adriana Faiella; Filomena Loffredo; Marco Salvatore; Roberto Pacelli
Journal:  Radiat Oncol       Date:  2013-09-23       Impact factor: 3.481

9.  Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount.

Authors:  Mark W Konijnenberg; Wout A P Breeman; Erik de Blois; Ho Sze Chan; Otto C Boerman; Peter Laverman; Petra Kolenc-Peitl; Marleen Melis; Marion de Jong
Journal:  EJNMMI Res       Date:  2014-08-30       Impact factor: 3.138

Review 10.  Hypofractionation in prostate cancer: radiobiological basis and clinical appliance.

Authors:  M Mangoni; I Desideri; B Detti; P Bonomo; D Greto; F Paiar; G Simontacchi; I Meattini; S Scoccianti; T Masoni; C Ciabatti; A Turkaj; S Serni; A Minervini; M Gacci; M Carini; L Livi
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.